Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

A new class of drugs with the potential to revolutionize the treatment of diseases ranging from cancer and Huntingtons disease to influenza has moved a step closer to the clinic, as  research reported in the past few weeks signals the removal of the most significant barrier to their use in humans.

In the new studies, researchers have demonstrated methods to effectively deliver treatments based on RNA interference, or RNAia natural process in which small, double-stranded RNA molecules shut down genes in a targeted manner. While both academic and commercial labs have had lab successes with RNAi since it was shown to work in human cells in 2001, efforts to turn the technique into drugs have been slowed by difficulties in getting the RNAs to where they need to be to provide their therapeutic benefit. RNA molecules tend to degrade quickly in the body, are hard to get inside cells, and are difficult to target to the right tissues.

But MIT immunologist Jianzhu Chen and colleagues have taken a giant step toward overcoming the delivery problem. In research published in the June 8 issue of the Proceedings of the National Academy of Sciences, Chen’s group successfully used a small polymer to deliver RNAs designed to block influenza infection into the lungs of mice. Chen injected a tiny amount of the RNA-polymer mixture into the animals veins; the polymer carried the RNA through the bloodstream and into the lungs, reducing the amount of virus found in the animals lungs as much as 1,000-fold. The RNAs protected the mice against both new and ongoing influenza infections, acting as either a short-term vaccine or a treatment. The MIT results are “very encouraging, says John Rossi, a molecular biologist investigating RNAi to treat HIV/AIDS at City of Hope hospital in Duarte, CA. It really goes to show that effective systemic delivery is possible.

Eric Manning, a biotech analyst at Navigant Consulting, shares that optimism. The polymers Chen uses seem to be more interesting to more people than we initially expected, he says. Manning believes such carriers are achieving better results than anticipated and may turn out to play a role in clinical applications of RNAi. Chens work goes a step further than a similar study in the same journal that used a high-pressure injection technique to deliver flu-defeating RNAs to mice. Although that method has been widely used in mouse studies of RNAi, the pressure and volume of fluid involved would not be practical in humans.

In another experiment, Chens group tried a different approach to deliver the RNAs: gene therapy. Instead of injecting the RNAs directly, the researchers used DNA molecules that coded for the anti-flu RNAs. Inside the mice, cellular machinery continually transcribes the DNA code into the active RNAs. To deliver the DNAs to the lungs, the researchers tested both the polymers used in the previous experiment as well as surfactant, a chemical used to prevent respiratory distress syndrome in premature babies. Both materials worked, though the polymers were more effective, yielding about a 100-fold reduction in the amount of virus present in the lungs.

The polymers Chen used are limited: they tend to deliver their loads preferentially to the lungs. But different methods of delivering RNAi-based treatments to other parts of the body have shown promise recently as well. In two additional studies, researchers have investigated different means of using gene therapy to deliver RNAi to treat brain cancer and a neurological disorder related to Huntingtons disease.

In work reported June 1 in the journal Clinical Cancer Research, William Pardridge of the University of California, Los Angeles, modified liposomesessentially tiny spheres of the molecules that make up cell membranesto target them specifically to human cancer cells implanted into the brains of mice. Two molecular homing signals called antibodies, normally produced by the immune system to fight infection, directed the liposomes first through the blood-brain barrier and then to the cancer cells. The spheres fused with the cancer cells and delivered their DNA load. The DNA encoded an RNA molecule designed to block a gene called EGFR, which runs amok in many kinds of cancer. Weekly injections more than doubled the survival time of the mice, from about 14 days to 31 days.

0 comments about this story. Start the discussion »

Tagged: Biomedicine

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me